Chemotherapy decisions and patient experience with the recurrence score assay for early‐stage breast cancer
Sign Up to like & getrecommendations! Published in 2017 at "Cancer"
DOI: 10.1002/cncr.30324
Abstract: The 21‐gene recurrence score (RS) assay stratifies early‐stage, estrogen receptor–positive breast cancer by recurrence risk. Few studies have examined the ways in which physicians use the RS to recommend adjuvant systemic chemotherapy or patients' experiences… read more here.
Keywords: recurrence score; recurrence; breast cancer; early stage ... See more keywords
Associations between use of the 21‐gene recurrence score assay and chemotherapy regimen selection in a statewide registry
Sign Up to like & getrecommendations! Published in 2017 at "Cancer"
DOI: 10.1002/cncr.30429
Abstract: The 21‐gene recurrence score (RS) assay predicts response to adjuvant chemotherapy in patients with early‐stage, hormone receptor‐positive, human epidermal growth factor receptor 2 (HER2)‐negative invasive breast cancer, but to the authors' knowledge, the role of… read more here.
Keywords: chemotherapy; chemotherapy regimen; gene recurrence; recurrence score ... See more keywords
Abstract PD7-05: How 21-gene recurrence score assay is being used to individualize adjuvant chemotherapy recommendations in ER+/HER2 -node positive breast cancer -A national cancer data base study
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs16-pd7-05
Abstract: Introduction: The 21-gene Recurrence Score (RS) assay has been shown in retrospective studies to predict benefit of adjuvant chemotherapy (AC) in node positive (N+) breast cancer (BC) patients (pts). This study evaluates the trends and… read more here.
Keywords: gene recurrence; breast cancer; recurrence score; cancer ... See more keywords
Abstract P4-12-05: Cost-effectiveness analysis of second-generation multi-gene expression prognostic assays compared with the standard 21-gene recurrence score assay to guide adjuvant therapy decisions in women with early stage breast cancer
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs17-p4-12-05
Abstract: Second-generation multi-gene expression assays can generate comprehensive molecular risk scores which may inform adjuvant chemotherapy decisions in women with early breast cancer. The 12-gene EPclin score assay (EndoPredict®) and 50-gene PAM50-risk of recurrence (ROR) score… read more here.
Keywords: ror score; cancer; gene; score ... See more keywords
Comparison of the Modified Immunohistochemical Marker Score and 21-Gene Recurrence Score Assay in Patients with Estrogen Receptor-Positive Breast Cancer
Sign Up to like & getrecommendations! Published in 2021 at "Oncology"
DOI: 10.1159/000521287
Abstract: Introduction: Not only the 21-gene recurrence score (RS) assay but also online prognostic tools and immunohistochemical prognostic models predict chemotherapy benefits for women with early breast cancer (BC). Multigene assays, including Oncotype DX, are expensive… read more here.
Keywords: breast cancer; patients estrogen; score; recurrence score ... See more keywords